GLP-1 receptor agonists like Ozempic (semaglutide) generated $18 billion in 2023 sales while post-market adverse event reports accelerated. The FDA received thousands of reports of gastroparesis (stomach paralysis), severe pancreatitis, bowel obstruction, and suicidal ideation — side effects that were either underrepresented or absent from clinical trial data. European regulators launched investigations into thyroid cancer links and suicidal thoughts. Novo Nordisk's stock reached record highs while patient advocacy groups argued the company minimized risk disclosures.